CardioVascular BioTherapeutics to Present at 2006 UBS Life Sciences Conference; President and CEO to Discuss Protein Drug Candidate to Treat Cardiovascular Disease.LAS VEGAS -- CardioVascular BioTherapeutics, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CVBT CVBT Cardiovascular Biotherapeutics, Inc CVBT Central Virginia Battlefields Trust (Fredericksburg, VA Civil War history organization) ) today announced that Daniel C. Montano, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. is presenting the progress of the company's drug candidates to treat cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease at the 2006 UBS UBS Union Bank of Switzerland UBS United Bible Societies UBS United Blood Services UBS United Buying Service UBS Used Bookstore UBS University Business Services UBS Universal Building Society (UK) UBS Ulaanbaatar Broadcasting System Global Life Sciences Conference. The event will be held from September 25 to 28 at the Grand Hyatt Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . Mr. Montano is scheduled to speak on September 25 at 8:30 a.m. The live audio webcast of Mr. Montano's presentation and the subsequent archived recording will be available on the "Investors" section of the company's website, at www.cvbt.com, and on the UBS Investment Bank website at www.ibb.ubs.com. "CardioVascular BioTherapeutics is dedicated to the development of therapies for the treatment of cardiovascular disease, which afflicts more than 71 million people in the US. We are making great strides in our FDA-authorized human clinical trials for our drug candidates with Cardio Vascu-Grow(TM) as the active ingredient, which is currently being investigated for its ability to stimulate the growth of new blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. to create perfusion of blood supply to impaired organs and tissues that could benefit from additional blood supply. I look forward to providing an update on our current FDA-authorized clinical trials and progress in our studies to treat a variety of cardio vascular diseases," said Mr. Montano. CVBT's Cardio Vascu-Grow(TM) contains a protein that is a member of the fibroblast growth factor Fibroblast growth factors, or FGFs, are a family of growth factors involved in wound healing and embryonic development. The FGFs are heparin-binding proteins and interactions with cell-surface associated heparan sulfate proteoglycans have been shown to be essential for FGF family that has been shown to stimulate the growth and multiplication of blood vessels, a process called angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. . When blood perfusion is established in affected areas, patients with cardiovascular diseases may experience an increase in life expectancy and quality of life. The UBS Life Sciences Conference is reported to be among the largest health care investor conferences in the world. It features presentations by more than 360 public and private companies representing biotechnology, medical device manufacturers, pharmaceuticals and specialty pharmaceutical. Senior executives from the leading pharmaceutical, biotechnology and medical technology companies will further provide their insight and outlook on the global life sciences industry. To access audio transmissions and the conference agenda please go to the UBS Investment Bank website at www.ibb.ubs.com. About CardioVascular BioTherapeutics CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow(TM) as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. The company is currently conducting two FDA-authorized clinical trials: one in coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. in no-option heart patients, and one in impaired wound healing seen in diabetics. Additionally, the company has completed pre-clinical studies in animal models of peripheral artery disease of the legs and stroke recovery. A foreign proof-of-concept clinical trial relating to chronic back pain believed to be caused by impaired or blocked lumbar arteries has also been initiated. Cardio Vascu-Grow is a trademark of CardioVascular BioTherapeutics, Inc. This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, results of future clinical and pre-clinical trials, differences in patient outcomes, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion